To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
MCU Floxed DAT-Cre Mouse*
Mouse Model
MCU Floxed DAT-Cre mice were generated by crossing floxed exons 5 and 6 of the MCU gene (Zampese et al. 2022) with mice expressing Cre recombinase under the dopaminergic-specific DAT to induce knock-out of MCU (mitochondrial Ca2+ uniporter), resulting in the loss of MCU specifically in dopaminergic cells. Model was designed by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038988
MCI-PARK Mouse*
Mouse Model
Homozygous knockout mice targeting Ndufs2 (NADH:ubquinone oxidoreductase core subunit S2) specifically in dopaminergic neurons. Mice with floxed Ndufs2 allele were crossed with mice expressing Cre recombinase under the control of Slc6ac (dopamine transporter; DAT) promoter. Model was generated and deposited by D. James Surmeier at Northwestern University through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:036313
Mfn2 LoxP Floxed Mouse*
Mouse Model
Mice with LoxP sites flanking Mfn2 exon 6. Model was generated and deposited by David Chan at California Institute of Technology through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:026525
PPMI iPSCs
Human iPS Cell
Induced pluripotent stem cell (iPSC) lines are available through the PPMI repository. The repository includes lines from control, idiopathic PD, genetic PD (LRRK2, GBA, SNCA), genetic unaffected carriers (LRRK2, LRRK2/GBA, GBA, SNCA), and prodromal patients. Gene-revertant controls are available for select lines. An inventory of available lines can be found here: https://zenodo.org/records/10607589
RILPL1 Antibody
Antibody
Rabbit monoclonal antibody directed against total rodent/human RILPL1 protein. Suitable for immunoblot, immunoprecipitation, and immunocytochemistry experiments.
SNCA Multiplication iPSC Lines*
Human iPS Cell
Isogenic iPSC lines harboring a triplication , duplication, single copy, or KO of the SNCA gene derived from a patient with the triplication mutation. These lines were generated and kindly deposited by Birgitt Schuele at Stanford University into the MJFF Sponsored Tools Program.
DJ-1 KO Rat*
Rat Model
Homozygous rat knockout of DJ-1 created by 8 base pair deletion plus 1 base pair substitution in Exon 5 in the Long Evans Hooded rat strain. RRID:RGD_7241048
Alpha-Synuclein A30P/A53T Mouse*
Mouse Model
Transgenic mice expressing double mutant form of human alpha synuclein containing A30P and A53T under the control of the rat tyrosine hydroxylase promoter. Model was generated and deposited by Eric Richfield at Rutger’s University through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:008239
Alpha-Synuclein A53T Knockin Mouse*
Mouse Model
Double transgenic homozygous mice which have PAC overexpression of human A53T alpha synuclein mutant form on an SNCA knockout mouse background. Model was generated and deposited by Robert Nussbaum at University of California San Francisco through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:010799
Alpha-Synuclein Knockout Mouse*
Mouse Model
SCNA knockout mice carrying a 1164 bp fragment deletion in exon 2. Model was generated and deposited by Vladimir Buchman at Cardiff University School of Biosciences through the MJFF Sponsored Tools Program (available through cryorecovery). RRID:IMSR_JAX:028559
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic